UKPDS Publications
Latest (2020- )
A brief history of the UK Prospective Diabetes Study
Holman RR., (2022), BRITISH JOURNAL OF DIABETES, 22, S32 - S35
Estimating risk factor progression equations for the UKPDS Outcomes Model 2 (UKPDS 90).
Leal J. et al, (2021), Diabet Med, 38
Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88.
Lind M. et al, (2021), Diabetes Care
Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89.
Wamil M. et al, (2021), Diabetes Care, 44, 1877 - 1884
Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus - A MASTERMIND precision medicine approach (UKPDS 87).
Agbaje OF. et al, (2020), Diabetes Res Clin Pract, 166
Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86).
Maddaloni E. et al, (2020), Lancet Diabetes Endocrinol, 8, 206 - 215
2010-2019
Long-term risk of cardiovascular disease in individuals with latent autoimmune diabetes in adults (UKPDS 85).
Maddaloni E. et al, (2019), Diabetes Obes Metab, 21, 2115 - 2122
Health selection into neighborhoods among patients enrolled in a clinical trial.
Arcaya MC. et al, (2017), Prev Med Rep, 8, 51 - 54
Microvascular outcomes in type 2 diabetes - Authors' reply.
Zoungas S. et al, (2017), Lancet Diabetes Endocrinol, 5
Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials.
Zoungas S. et al, (2017), Lancet Diabetes Endocrinol, 5, 431 - 437
The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84).
Alva ML. et al, (2015), Diabet Med, 32, 459 - 466
Performance of the UKPDS outcomes model for prediction of myocardial infarction and stroke in the ADDITION-Europe trial cohort: does the ADDITION validation add up?
Gray A. et al, (2014), Value Health, 17, 895 - 896
Ethnicity and long-term vascular outcomes in Type 2 diabetes: A prospective observational study (UKPDS 83)
Davis TME. et al, (2014), Diabetic Medicine, 31, 200 - 207
UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82.
Hayes AJ. et al, (2013), Diabetologia, 56, 1925 - 1933
Temporal validation of the UKPDS outcomes model using 10-year posttrial monitoring data.
Leal J. et al, (2013), Diabetes Care, 36, 1541 - 1546
Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79.
Davis TME. et al, (2013), Circulation, 127, 980 - 987
2005-2009
Intensive glucose control and macrovascular outcomes in type 2 diabetes.
Control Group None. et al, (2009), Diabetologia, 52, 2288 - 2298
Follow-up of Intensive Glucose Control in Type 2 Diabetes Reply
Holman RR. et al, (2009), NEW ENGLAND JOURNAL OF MEDICINE, 360, 418 - 418
Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75).
Stratton IM. et al, (2006), Diabetologia, 49, 1761 - 1769
Risk factors for renal dysfunction in type 2 diabetes: U.K. prospective diabetes study 74. (Diabetes (2006) 55, (1832-1839))
Retnakaran R. et al, (2011), Diabetes, 60
The variable number of tandem repeats upstream of the insulin gene is a susceptibility locus for latent autoimmune diabetes in adults.
Desai M. et al, (2006), Diabetes, 55, 1890 - 1894
Long-term efficacy of sulfonylureas: a United Kingdom Prospective Diabetes Study perspective.
Holman RR., (2006), Metabolism, 55, S2 - S5
Reporting of diabetes on death certificates using data from the UK Prospective Diabetes Study.
Thomason MJ. et al, (2005), Diabet Med, 22, 1031 - 1036
Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).
Clarke PM. et al, (2005), Diabetologia, 48, 868 - 877
IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71) (vol 48, pg 703, 2005)
Bottazzo GF. et al, (2005), DIABETOLOGIA, 48, 1240 - 1240
Islet autoantibodies in clinically diagnosed type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70).
Davis TME. et al, (2005), Diabetologia, 48, 695 - 702
Insulin sensitivity at diagnosis of Type 2 diabetes is not associated with subsequent cardiovascular disease (UKPDS 67).
Adler AI. et al, (2005), Diabet Med, 22, 306 - 311
10-year follow-up of intensive glucose control in type 2 diabetes.
Holman RR. et al, (2008), N Engl J Med, 359, 1577 - 1589
Long-term follow-up after tight control of blood pressure in type 2 diabetes.
Holman RR. et al, (2008), N Engl J Med, 359, 1565 - 1576
Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study 78.
Cull CA. et al, (2007), Circulation, 116, 2119 - 2126
An association analysis of the HLA gene region in latent autoimmune diabetes in adults.
Desai M. et al, (2007), Diabetologia, 50, 68 - 73
Metformin as first choice in oral diabetes treatment: the UKPDS experience.
Holman R., (2007), Journ Annu Diabetol Hotel Dieu, 13 - 20
Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes: UKPDS 76.
Calle R. et al, (2006), Diabetologia, 49, 2892 - 2899
Hypoglycemia in Type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73.
Wright AD. et al, (2006), J Diabetes Complications, 20, 395 - 401
A clinical screening tool identifies autoimmune diabetes in adults: response to Fourlanos et al.
Davis TME. et al, (2006), Diabetes Care, 29
2002-2004
Changing aspirin use in patients with Type 2 diabetes in the UKPDS.
Cull CA. et al, (2004), Diabet Med, 21, 1368 - 1371
Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.
Matthews DR. et al, (2004), Arch Ophthalmol, 122, 1631 - 1640
Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes?: U.K. prospective diabetes study 61.
Colagiuri S. et al, (2002), Diabetes Care, 25, 1410 - 1417
Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62).
Clarke P. et al, (2002), Med Decis Making, 22, 340 - 349
UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine.
Kothari V. et al, (2002), Stroke, 33, 1776 - 1781
UKPDS 59: hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes.
Adler AI. et al, (2002), Diabetes Care, 25, 894 - 899
Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57).
Wright A. et al, (2002), Diabetes Care, 25, 330 - 336
Calculation of coronary risk in Type II diabetes: another cause for concern.
Saeed BO. et al, (2002), Clin Sci (Lond), 103, 217 - 219
Calculation of coronary risk in Type II diabetes: another cause for concern: authors' reply
Holman RR. et al, (2002), CLINICAL SCIENCE, 103, 219 - 219
A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68).
Clarke PM. et al, (2004), Diabetologia, 47, 1747 - 1759
Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66.
Stevens RJ. et al, (2004), Diabetes Care, 27, 201 - 207
Poor pregnancy outcome for women with Type 2 diabetes.
Hadden DR. et al, (2003), Diabet Med, 20, 506 - 507
The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65).
Clarke P. et al, (2003), Diabet Med, 20, 442 - 450
Autoantibodies to the islet cell antigen SOX-13 are associated with duration but not type of diabetes.
Davis TME. et al, (2003), Diabet Med, 20, 198 - 204
Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).
Adler AI. et al, (2003), Kidney Int, 63, 225 - 232
UKPDS58--modeling glucose exposure as a risk factor for photocoagulation in type 2 diabetes.
Stevens RJ. et al, (2002), J Diabetes Complications, 16, 371 - 376
2001
The UKPDS: implications for the dyslipidaemic patient.
Holman R., (2001), Acta Diabetol, 38 Suppl 1, S9 - 14
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56).
Stevens RJ. et al, (2001), Clin Sci (Lond), 101, 671 - 679
Erratum: The UKPDS risk engine: A model for the risk of coronary heart disease in type II diabetes (UKPDS 56) (Clinical Science (2001) 101 (671-679))
Stevens RI. et al, (2002), Clinical Science, 102
Underestimation of the importance of homocysteine as a risk factor for cardiovascular disease in epidemiological studies.
Clarke R. et al, (2001), J Cardiovasc Risk, 8, 363 - 369
Butyrylcholinesterase K variant on chromosome 3 q is associated with Type II diabetes in white Caucasian subjects.
Hashim Y. et al, (2001), Diabetologia, 44, 2227 - 2230
An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).
Gray A. et al, (2001), Diabet Med, 18, 438 - 444
Relationship between the severity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS (UKPDS 52).
Kohner EM. et al, (2001), Diabet Med, 18, 178 - 184
Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
Clarke P. et al, (2001), Diabetologia, 44, 298 - 304
UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis.
Stratton IM. et al, (2001), Diabetologia, 44, 156 - 163
2000
Life-expectancy projection by modelling and computer simulation (UKPDS 46).
Stevens R. et al, (2000), Diabetes Res Clin Pract, 50 Suppl 3, S5 - 13
Seeing what you want to see in randomised controlled trials. Authors' choice of study was ill informed.
Holman R., (2000), BMJ, 321, 1078 - 1079
Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study.
Adler AI. et al, (2000), BMJ, 321, 412 - 419
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.
Stratton IM. et al, (2000), BMJ, 321, 405 - 412
Effects of three months' diet after diagnosis of Type 2 diabetes on plasma lipids and lipoproteins (UKPDS 45)
Manley SE. et al, (2000), Diabetic Medicine, 17, 518 - 523
1999
Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom Prospective Diabetes Study (UKPDS 47)
Adler AI. et al, (1999), American Heart Journal, 138, S353 - S359
Microaneurysms in the development of diabetic retinopathy (UKPDS 42). UK Prospective Diabetes Study Group.
Kohner EM. et al, (1999), Diabetologia, 42, 1107 - 1112
Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49)
Turner RC. et al, (1999), Journal of the American Medical Association, 281, 2005 - 2012
Genetic heterogeneity of autoimmune diabetes: age of presentation in adults is influenced by HLA DRB1 and DQB1 genotypes (UKPDS 43). UK Prospective Diabetes Study (UKPDS) Group.
Horton V. et al, (1999), Diabetologia, 42, 608 - 616
1998
Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40
Gray A., (1998), British Medical Journal, 317, 720 - 726
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
Turner RC. et al, (1998), LANCET, 352, 837 - 853
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)
Turner RC. et al, (1998), LANCET, 352, 854 - 865
UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
Matthews DR. et al, (1998), Diabetic Medicine, 15, 297 - 303
Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)
Turner RC. et al, (1998), BMJ, 316, 823 - 828
United Kingdom Prospective Diabetes Study, 30: diabetic retinopathy at diagnosis of non-insulin-dependent diabetes mellitus and associated risk factors.
Kohner EM. et al, (1998), Arch Ophthalmol, 116, 297 - 303
United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.
(1998), Ann Intern Med, 128, 165 - 175
UKPDS 28: A randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes
Wright AD. et al, (1998), Diabetes Care, 21, 87 - 92
1997
UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes. UK Prospective Diabetes Study Group.
Turner R. et al, (1997), Lancet, 350, 1288 - 1293
U.K. Prospective Diabetes Study 27: Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex
(1997), Diabetes Care, 20, 1683 - 1687
U.K. Prospective Diabetes Study 22. Effect of age at diagnosis on diabetic tissue damage during the first 6 years of NIDDM.
Davis TM. et al, (1997), Diabetes Care, 20, 1435 - 1441
Coronary heart disease and risk factors in NIDDM--experience from the United Kingdom Prospective Diabetes Study.
Turner RC. et al, (1997), Diabetologia, 40 Suppl 2, S121 - S122
UKPDS 20: plasma leptin, obesity, and plasma insulin in type 2 diabetic subjects.
Widjaja A. et al, (1997), J Clin Endocrinol Metab, 82, 654 - 657
1996
Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control.
(1996), Diabetologia, 39, 1554 - 1561
The UK Prospective Diabetes Study
Turner RC. and Holman RR., (1996), Annals of Medicine, 28, 439 - 444
UKPDS 18: Estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
Eeley EA. et al, (1996), DIABETIC MEDICINE, 13, 656 - 662
United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus.
Turner R. et al, (1996), Ann Intern Med, 124, 136 - 145